ArticleCell2018
Protein Interaction Mapping Identifies RBBP6 as a Negative Regulator of Ebola Virus Replication.
Open access · bronzeAbstract read
In one paragraph
Article in Cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers.
0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed
9.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 152 citations in OpenAlex.
- Disruption of ER-mitochondria contact sites by coronavirus replication organelles sustains viral replication via NSP3 stabilization.The EMBO journal · 2026Article
- Temporal transcriptomics identifies early-response and infection-condition-specific modules guiding host-directed anti-EBOV therapeutics.Microbiology spectrum · 2026Article
- ProtFormer-Site: Ultra-fast and Accurate Prediction of Protein-Protein Interaction Sites with Protein Language Model.Interdisciplinary sciences, computational life sciences · 2026Article
- Infection-sensing minigenome as a novel therapeutic approach against Ebola virus.Molecular therapy. Nucleic acids · 2025Article
- Analysis of the Porcine Reproductive and Respiratory Syndrome Virus Nucleocapsid Interactome.Journal of proteome research · 2025Article
- 25 Years of Ebola Virus VP35 Research.Journal of molecular biology · 2025Review
- A comprehensive PDCoV-host proteome interaction map reveals potential antiviral targets.PLoS pathogens · 2025Article
- Ebola virus VP35 NNLNS motif modulates viral RNA synthesis and MIB2-mediated signaling.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- A protein-proximity screen reveals Ebola virus co-opts the mRNA decapping complex through the scaffold protein EDC4.Nature communications · 2025Article
- DeepHVI: A multimodal deep learning framework for predicting human-virus protein-protein interactions using protein language models.Biosafety and health · 2025Article
- The coming era of proteomics-driven precision medicine.National science review · 2025Review
- Single-cell image-based screens identify host regulators of Ebola virus infection dynamics.Nature microbiology · 2025Article
- Article
- Structural host-virus interactome profiling of intact infected cells.Nature communications · 2025Article
- Yellow Fever Virus Interactomes Reveal Common and Divergent Strategies of Replication and Evolution for Mosquito-borne Flaviviruses.bioRxiv : the preprint server for biology · 2025Article
- AlphaFold models of host-pathogen interactions elucidate the prevalence and structural modes of molecular mimicry.bioRxiv : the preprint server for biology · 2025Article
- FGF2 Mediated USP42-PPARγ Axis Activation Ameliorates Liver Oxidative Damage and Promotes Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- N Protein of Tomato Spotted Wilt Virus Proven to Be Antagonistic Against Tomato Yellow Leaf Curl Virus in Nicotiana benthamiana.Molecular plant pathology · 2025Article
- Whole-cell response of coronavirus-infected BMDCs through proteomic and transcriptomic analyses.Frontiers in immunology · 2025Article
- Proximity Proteomics to Profile Ebola Virus Protein Interactome in Its Functional Context.Methods in molecular biology (Clifton, N.J.) · 2025Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
23 authors at 8 institutions in 1 country.
Jyoti BatraCenter for Microbial Pathogenesis, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA; Quantitative Biosciences Institute, University of California, San Francisco, San Francisco, CA 94158, USA; J. David Gladstone Institutes, San Francisco, CA 94158, USA.
Judd F HultquistDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Quantitative Biosciences Institute, University of California, San Francisco, San Francisco, CA 94158, USA; J. David Gladstone Institutes, San Francisco, CA 94158, USA; Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Dandan LiuDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63105, USA.
Olena ShtankoDepartment of Virology and Immunology, Texas Biomedical Research Institute, San Antonio, TX 78245, USA.
John Von DollenDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Quantitative Biosciences Institute, University of California, San Francisco, San Francisco, CA 94158, USA; J. David Gladstone Institutes, San Francisco, CA 94158, USA.
Laura SatkampDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Quantitative Biosciences Institute, University of California, San Francisco, San Francisco, CA 94158, USA; J. David Gladstone Institutes, San Francisco, CA 94158, USA.
Gwendolyn M JangDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Quantitative Biosciences Institute, University of California, San Francisco, San Francisco, CA 94158, USA; J. David Gladstone Institutes, San Francisco, CA 94158, USA.
Priya LuthraCenter for Microbial Pathogenesis, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.
Toni M SchwarzDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Gabriel I SmallDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63105, USA.
Eusondia ArnettTexas Biomedical Research Institute, San Antonio, TX 78245, USA.
Manu AnantpadmaDepartment of Virology and Immunology, Texas Biomedical Research Institute, San Antonio, TX 78245, USA.
Ann ReyesDepartment of Virology and Immunology, Texas Biomedical Research Institute, San Antonio, TX 78245, USA.
Daisy W LeungDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63105, USA.
Robyn KaakeDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Quantitative Biosciences Institute, University of California, San Francisco, San Francisco, CA 94158, USA; J. David Gladstone Institutes, San Francisco, CA 94158, USA.
Paige HaasDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Quantitative Biosciences Institute, University of California, San Francisco, San Francisco, CA 94158, USA; J. David Gladstone Institutes, San Francisco, CA 94158, USA.
Carson B SchmidtDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Quantitative Biosciences Institute, University of California, San Francisco, San Francisco, CA 94158, USA; J. David Gladstone Institutes, San Francisco, CA 94158, USA.
Larry S SchlesingerTexas Biomedical Research Institute, San Antonio, TX 78245, USA.
Douglas J LaCountDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907, USA.
Robert A DaveyDepartment of Virology and Immunology, Texas Biomedical Research Institute, San Antonio, TX 78245, USA.
Gaya K AmarasingheDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63105, USA.
Christopher F BaslerCenter for Microbial Pathogenesis, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA. Electronic address: cbasler@gsu.edu.
Nevan J KroganDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Quantitative Biosciences Institute, University of California, San Francisco, San Francisco, CA 94158, USA; J. David Gladstone Institutes, San Francisco, CA 94158, USA. Electronic address: nevan.krogan@ucsf.edu.
Texas Biomedical Research Institute · USWashington University in St. Louis · USGladstone Institutes · USQuantitative BioSciences · USUniversity of California, San Francisco · USGeorgia State University · USIcahn School of Medicine at Mount Sinai · USPurdue University West Lafayette · US
Funding
X-ray Screening and Rapid Structure DeterminationP50GM082250 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FRANKEL, ALAN D · 2007 to 2018
$48.8MThe role of Listeria cyclic-di-AMP during infection and immunityP01AI063302 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI STANLEY, SARAH A · 2004 to 2025
$45.5MVirology BSL4 CoreP01AI120943 · NIAID · WASHINGTON UNIVERSITY · PI Gaya K. Amarasinghe · 2016 to 2026
$30.2MVirus CoreU19AI106754 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ALBRECHT, RANDY A. · 2013 to 2017
$26.0MRESEARCH PROJECT 2U19AI135990 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JEFFERY S COX · 2018 to 2026
$21.4MTherapeutics Targeting Filoviral interferon-antagonist and replication functionsU19AI109664 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BASLER, CHRISTOPHER F · 2014 to 2018
$15.8MMolecular mechanisms of immune dysregulation by filoviral interferon U19AI109945 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BASLER, CHRISTOPHER F · 2014 to 2018
$9.5MMicrobial Pathogenesis and Host DefenseT32AI060537 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joanne N. Engel · 2004 to 2026
$6.5MNovel VP30-host Interactions that Negatively Regulate Ebola Virus InfectionR01AI143292 · NIAID · WASHINGTON UNIVERSITY · PI AMARASINGHE, GAYA K., BASLER, CHRISTOPHER F · 2019 to 2023
$4.0MEmerging virus-host cell protein interaction networksR01AI114814 · NIAID · PURDUE UNIVERSITY · PI DAVEY, ROBERT A, LACOUNT, DOUGLAS J. · 2015 to 2019
$3.5MDiscovery of novel, ubiquitin-regulated mechanisms of TB control by macrophagesR01AI120694 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COX, JEFFERY S, KROGAN, NEVAN J · 2015 to 2019
$3.3MPerturbing virus replication with interfering peptidesR21AI166736 · NIAID · PURDUE UNIVERSITY · PI LACOUNT, DOUGLAS J. · 2022 to 2023
$451kHoward Hughes Medical InstituteNIAID NIH HHS P01 AI063302NIAID NIH HHS P01 AI120943NIAID NIH HHS R01 AI114814NIAID NIH HHS R01 AI120694NIAID NIH HHS R01 AI143292NIAID NIH HHS R21 AI166736NIAID NIH HHS T32 AI060537NIAID NIH HHS U19 AI106754NIAID NIH HHS U19 AI109664NIAID NIH HHS U19 AI109945NIAID NIH HHS U19 AI135990NIGMS NIH HHS P50 GM082250
Abstract
Ebola virus (EBOV) infection often results in fatal illness in humans, yet little is known about how EBOV usurps host pathways during infection. To address this, we used affinity tag-purification mass spectrometry (AP-MS) to generate an EBOV-host protein-protein interaction (PPI) map. We uncovered 194 high-confidence EBOV-human PPIs, including one between the viral transcription regulator VP30 and the host ubiquitin ligase RBBP6. Domain mapping identified a 23 amino acid region within RBBP6 that binds to VP30. A crystal structure of the VP30-RBBP6 peptide complex revealed that RBBP6 mimics the viral nucleoprotein (NP) binding to the same interface of VP30. Knockdown of endogenous RBBP6 stimulated viral transcription and increased EBOV replication, whereas overexpression of either RBBP6 or the peptide strongly inhibited both. These results demonstrate the therapeutic potential of biologics that target this interface and identify additional PPIs that may be leveraged for novel therapeutic strategies.
Indexed as
Carrier ProteinsDNA-Binding ProteinsTranscription FactorsViral ProteinsCrystallography, X-RayEbolavirusHEK293 CellsHeLa CellsHemorrhagic Fever, EbolaHumansProtein Interaction MappingUbiquitin-Protein LigasesVirus ReplicationCarrier ProteinsDNA-Binding ProteinsRBBP6 protein, humanTranscription FactorsUbiquitin-Protein LigasesViral ProteinsVP30 protein, ebola virusantiviral factorEbola virushost-pathogen interactionsprotein-protein interactionsRBBP6RNA virusesvirus-host interactionsVP30
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.